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Monitoring change in volume of
calcifications in juvenile idiopathic
inflammatory myopathy: a pilot study using
low dose computed tomography
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Ira N. Targoff6 and Lauren M. Pachman4*

Abstract
Background: Dystrophic calcifications may occur in patients with J uvenile Idiopathic Inflammatory Myopathy (JIIM) as
well as other connective tissue and metabolic diseases, but a reliable method of measuring the volume of these
calcifications has not been established. The purpose of this study is to determine the feasibility of low dose, limited
slice, Computed Tomography (CT) to measure objectively in-situ calcification volumes in patients with JIIM over time.
Methods: Ten JIIM patients (eight JDM, two Overlap) with calcifications were prospectively recruited over a 2-year
period to undergo two limited, low dose, four-slice CT scans. Calculation of the volume of calcifications used a CT post
processing workstation. Additional patient data included: Disease Activity Scores (DAS), Childhood Myositis Assessment
Scale (CMAS), myositis specific antibodies (MSA), and the TNFα-308 promoter region A/G polymorphism. Statistical
analysis utilized the Pearson correlation coefficient, the paired t-test and descriptive statistics.
Results: Ten JIIM, mean age 14.54 ± 4.54 years, had a duration of untreated disease of 8.68 ± 5.65 months MSA status:
U1RNP (1), PM-Scl (1), Ro (1, 4 indeterminate), p155/140 (2), MJ (3), Mi-2 indeterminate (1), negative (3). 4/8 JDM (50%)
were TNF-α-308 A+. Overall, the calcification volumes tended to decrease from the first to the second CT study by 0.
5 cm3 (from 2.79 ± 1.98 cm3 to 2.29 ± 2.25 cm3). The average effective radiation dose was 0.007 ± 0.002, 0.010 ± 0.005,
and 0.245 mSv for the upper extremity, lower extremity and chest, respectively (compared to a standard chest x-ray– 0.
02mSV effective dosage).
Conclusion: We conclude: 1) the limited low dose CT technique provides objective data about volume of the
calcifications in JIIM; 2) measuring the volume of calcifications in an extremity is associated with minimal radiation
exposure; 3) This method may be useful to evaluate the efficacy of therapies for JIIM dystrophic calcification.
Keywords: Computed Tomography (CT), Calcification volume, Juvenile idiopathic inflammatory myopathy, Overlap
syndrome, Calcification
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Background
In children with JIIM, such as Juvenile Dermatomyositis
(JDM) and Overlap Syndrome, dystrophic calcifications
are a common and debilitating complication. The reported calcifications in JDM range from 71% [1] to 8%
[2] with 40% most frequently cited [3]. These calcifications usually occur in children with chronic inflammation and hypoxia associated with JIIM, which includes
JDM, Polymyositis and Overlap Syndromes as well as in
patients with other rheumatic diseases such as Scleroderma [4] and Systemic Lupus Erythematosus [5, 6].
Plain radiography is effective for the detection of calcinosis and the categorization of morphological patterns
of calcification [7]. Although radiography is recommended
for the initial imaging of calcinosis, it fails to evaluate objectively the volume of calcifications. Case reports have
employed different types of whole body scans (scintigraphy
using Technetium methylene diphosphonate (Tc-99 m
MDP) and Tc-99 m pyrophosphate and Strontium nitrate)
in an attempt to identify the location of the calcifications
and to provide a quantifiable assessment of their extent, as
well as to develop a method to monitor the child’s therapeutic response [8]. Scintigraphic evaluation using Tc-99 m
MDP can effectively delineate sites of dystrophic calcifications in JDM and it is more sensitive in detecting visceral
calcifications than plain radiographs [9]. However, scintigraphy has failed to provide a quantitative estimation of the
volume of the calcification. In contrast, micro CT and
synchrotron x-ray diffraction studies of calcified deposit
samples from four children with the diagnosis of JDM
characterized the microstructure of calcinosis, and
demonstrated excellent sensitivity with respect to quantitation of amount and spatial distribution of minerals in
these calcifications samples [10]. These studies suggested
that CT could be used to measure the calcifications occurring in the soft tissues of children with JIIM, as this
method had been effective in the experimental mouse
model [11].
The purpose of this pilot study was to determine the
feasibility of the use of low dose, limited slice CT as an
objective measure of in-situ calcification volume, over
time, in patients with JIIM.
Methods
Patient population

Approval was obtained from the Ann & Robert H. Lurie
Children’s Hospital of Chicago Institutional Review Board
to perform this prospective study (IRB#2008-13316).
Inclusion criteria for study enrollment consisted of a
diagnosis of JIIM and documentation of moderate to
severe calcifications as determined by the assessor on
clinical evaluation. One hundred and fifty JIIM patients
were followed in our clinic during the time of the study.
Of those, 14 (9.3%) had moderate to severe calcification;
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ten of these children were available for study; they gave
their consent and were enrolled in the study. Eight of
these children had severe calcifications and fulfilled the
Peter and Bohan [12] criteria for definite/possible JDM
and two of the patients had Overlap Syndrome and moderate calcifications. The duration of untreated disease was
given by the patient's family. Each of the ten cases had
two scans over a 2 year period. For consistency purposes,
a single individual, the principal investigator (PI), marked
the specific accessible area of the calcification to be
scanned. The PI performed a complete physical examination; anatomic landmarks of the area were noted as a reference point for future scans.
Laboratory assessment
TNF-α-308 promoter polymorphism

The A/G polymorphism in the −308 promoter region
was determined by PCR, following established methodology [13].
Myositis Specific Antibody (MSA)

Each patient’s sera was analyzed at diagnosis and periodically thereafter, as new antibodies were recognized, by
the Oklahoma Medical Research Foundation Clinical
Immunology Laboratory, following methods previously
outlined [14, 15].
Clinical assessment
Disease Activity Scores (DAS)

The patient’s status with respect to 1) total DAS score;
2) skin involvement (DAS-S) as well as, 3) muscle strength
and endurance (DAS-M) was assessed at the time of every
visit according to a standard protocol [16].
The Childhood Myositis Assessment Score (CMAS)

An estimate of performance was obtained at every visit by a
physical therapist, who was an independent observer [17].
Imaging of calcifications

A limited four-slice CT was performed on a Siemens
Somatom Sensation 64 CT scanner in the area of greatest
calcium burden and utilized 100kVp, 100 mAs, 3 mm reconstructed slice thickness. Only the limb of interest was
included in the scan field of view. For example, examination of the arm was performed in an image “arms-overhead” stance instead of alongside of the body to limit radiation exposure of the torso. The area of soft tissue calcifications was determined by thresholding the calcifications
from the range of Hounsfield units of the calcifications
(114–3017 Hounsfield units) using software on a Siemens
CT workstation (MMWP, Siemens Medical Solutions,
Malvern, PA). No sedation was required. There was a
mean interval of 7.18 ± 2.33 months between the first scan
and second scans. The computed tomography dose index
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(CTDI) and the dose length product (DLP) were reported
by the scanner. The DLP was used to estimate the patient
effective dose using published methods [18, 19] for the
chest and lower extremities. Due to a paucity of data on
the subject, estimates of the upper extremity effective dose
were performed by a physicist based on published conversion factors for lower extremities [18, 19].
Statistical analysis

Presentation of demographic and baseline characteristics
used descriptive statistics. A paired t-test analyzed volume changes of calcifications in JIIM patients over time.
Pearson correlation coefficient was used to determine
the correlation between change in calcification volume
and duration of active disease.

Results

which was consistent with our previous findings [20]. Before entering the study, the patients had been given a variety of medications including; methotrexate (n = 7),
hydroxychloroquine (n = 6), cyclosporine (n = 4), mycophenolate mofetil (MMF) (n = 4), prednisone (n = 6),
intravenous methylprednisolone (n = 2) and intravenous
gamma globulin (IVIG) (n = 2). During the study, the following medications were added: prednisone (n = 2), intravenous methylprednisolone (n = 3) and MMF (n = 3). All
the children with calcifications were placed on at least two
medications, but only five had been given a high dose
intermittent pulse methylprednisolone. By end of the
study, a total of six children had been given MMF,
which did improve their rash [21]. Of note, the four
patients for whom cyclosporine was proscribed stated
that they were non-compliant with respect to the cyclosporine and had low serum levels of the drug.

Demographics and disease state

The demographics of the ten patients enrolled in this
proof of principle study are presented in Table 1. The
patients had active inflammatory disease for a mean of
8.68 ± 5.65 months. At the time of both scans, the patients still displayed symptoms of moderately active JIIM.
Their DAS-S and DAS-M at the first scan were 6 ± 2.3
and 3 ± 3.7 respectively; (maximal DAS-M = 11, maximal DAS-S = 9; normal = 0 for both DAS-S and DASM) with a CMAS of 43 ± 7.4 (normal CMAS = 52). At
the time of the second scan, their disease activity demonstrated very little improvement (DAS-S = 5 ± 2.2, DASM = 3 ± 2.7, CMAS = 44 ± 9.5). Two of the ten patients
had Overlap Syndrome, one each positive for either
Pm/SCL or U1RNP indeterminate. The remainder of
the group was classified as JDM (4 Ro indeterminate; 1
Mi-2 indeterminate; three MJ positive; two p155/140
positive, one Ro positive; three negative for MSA). Of
the ten subjects, eight had JDM and 4/8 (50%) were positive for TNF-α-308 GA polymorphism, the rest were GG,

Calcifications and CT scanning data

The calcifications were located as follows: three above
the elbow, two in the forearm, one at the elbow, one in
the area of the tibia, two around the knee and one in the
chest wall. The average CTDI and DLP for the upper extremity (n = 12), lower extremity (n = 6) and chest (n = 1)
are presented in Table 2.
Table 2. The CTDI and DLP are relatively similar for
upper and lower extremities scanned in this study but
the chest has a higher effective dose than the extremity
studies. It is important to note, for comparison, that the
comparable average effective radiation dose for a 15 year
old child’s standard chest x-ray is 0.02 mSv [22], compared
to the average effective doses above for the extremities of
0.007 and 0.010mSV), where the majority of the calcifications occur. Figure 1a presents an axial CT image of the
upper arm showing a large cluster of calcifications medially, while Fig. 1b depicts the same axial CT image showing the calculated calcification volume highlighted in gray.

Table 1 Clinical features of patients with juvenile idiopathic inflammatory myopathy
Gender Diagnosis Duration of untreated Location of MSA status
disease (DUD) (mo)
calcification

TNF-α-308 Age at scan 1 (years) Age at scan 2 (years)

Case 1

F

JDM

2.00

Arm

Ro indeterminate, MJ+ GG

Case 2

M

JDM

2.99

Forearm

Ro indeterminate, MJ+ GG

13.94

14.43

Case 3

F

JDM

2.00

Forearm

Ro indeterminate,
p155/140+

10.93

11.43

Case 4

M

JDM

0.36

Tibia

Mi-2 indeterminate

GA

16.32

16.86

Case 5

F

JDM

14.32

Knee

Negative

GG

8.89

9.48

Case 6

F

JDM

16.99

Arm

Negative

GG

20.58

21.17

Case 7

F

OVERLAP

0.00

Elbow

PMScl+

GG

13.72

14.35

Case 8

F

JDM

11.99

Knee

Negative

GA

20.06

20.73

Case 9

F

OVERLAP

10.05

Chest

U1RNP indeterminate, GG
Ro indeterminate, MJ+

20.27

20.93

JDM

20.04

Arm

Ro+, p155/140+

9.46

9.88

Case 10 F

GA

GA

11.25

11.71
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Table 2 Average radiation dose estimates by CT scan location
Total number of scans

Average CTDI mGy (stdv)

Average DLP mGyacm (stdv)

Average effective dose mSv (stdv)

Upper extremity

12

4.322 (1.656)

16.133 (4.770)

0.007 (0.002)

Lower extremity

6

4.283 (0.581)

18.167 (3.488)

0.010 (0.005)

1

4.200

17.000

0.245

a

Chest
a

missing radiation information from first scan

The volume of the calcifications

There was a positive association of the change of the
volume of calcification and DUD although this association was not statically significant (correlation 0.27, p =
0.46 Pearson correlation coefficient), (Fig. 2). The average size of calcifications at the first scan was 2.79 ± 1.98
and 2.29 ± 2.25 cm3 at the second scan, for an average decrease in size of 0.51 ± 1.38 cm3 (approximately 18%).
However, the 6/10 who were compliant with their medications, did have a decrease in calcification volume from
2.32 ± 1.77 cm3 on the first scan to 1.00 ± 0.92 cm3 on
the second scan, which was a measurable average decrease of 1.32 ± 1.14 cm3 (Fig. 3).

Discussion
The present study represents the first pilot study to
evaluate objectively the volume of calcifications in patients with JIIM over time. The mechanisms controlling
the pathophysiology of calcifications remain poorly understood. Studies of the composition of these calcifications
have shown that hydroxyapatite is the main mineral component, as well as calcium carbonate [23, 24]. Other bone
matrix proteins such as osteonectin, osteopontin and bone
sialoprotein have been documented [24], in addition to
members of the integrin family [25]. Reported risk factors
for the development of calcinosis include delayed diagnosis and treatment along with inadequate levels and duration of immunosuppressive therapy, [26] suggesting that
prolonged inflammation contributes to tissue injury which
promotes the calcium deposition. A common feature
among all the children in this study was the persistent and
chronic course of an active inflammatory process, which

may be a major factor in the development/progression of
calcifications in children with myositis [20]. Thirty percent
of the JIIM group had a substitution of A at the TNFα308 promoter region, which is similar to the 27–30%
frequency in the general population, while 50% of the
patients with JDM (4/8) were positive for the A substitution [20].
This study was not designed to test the efficacy of specific agents to elicit change in the volume of the calcifications, but to document that the single slice CT gives
sufficient information to evaluate and compare outcomes. Our analysis of 20 CT scans of patients with JIIM
and calcifications during a 2 year period while they were
given immunosuppressive therapy showed a tendency
for the specific calcification to decrease in volume in
that time frame. In this group, 6/10 had positive MSAs,
of whom 3/8 JDM were positive for one of the more frequently occurring MSAs, anti-MJ, reported to be associated with calcification [27].
We are not aware of any previous study that has used
an objective method to measure the volume of calcifications embedded in the soft tissue of children with JIIM.
For patients with systemic sclerosis, multidector computed
tomography with multiplanar format has been employed
successfully [28]. Experimentally, microcomputed tomography was employed to measure the volume of calcification
in Abcc6 deficient mice [29] and to monitor the rate of
resolution of induced calcification in mice with defective
macrophage function [11].
Effective radiation dose in CT is dependent on three
primary factors: the amount of radiation necessary to
achieve the desired contrast between tissues, the extent

Fig. 1 a Axial CT image of the upper arm of a child with JDM, showing a large cluster of calcifications medially. b The same axial CT image showing
the calculated calcification volume highlighted in gray
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Fig. 2 Black dots represent children with JDM. Black dots in a triangle
represent two children with overlap syndromes (Pm-Scl and U1RNP)

of the body that is included in the field-of-view and the
types of organs exposed to the radiation. The exceptionally low radiation dose needed to acquire the images in
this study is a result of the favorable constitution, size,
and location of JIIM calcifications. First, by their very
nature –the deposits contain calcium (and are therefore
comparatively radiopaque)– the calcifications are a strong
contrast when compared to surrounding soft tissue
(similar to bone). For this reason, very little radiation
dose is needed to achieve excellent subject contrast and
subsequent volume delineation; this was reflected in
the reported CTDI value, which was low. Second, the
physical size of the calcifications was easily captured in
a 12 mm z-axis length, therefore limiting the radiation
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exposure to a very small anatomical region, which is
reflected in the low DLP of this study. Finally, the JIIM
calcifications in this study were located primarily in the
extremities, which are relatively radio-insensitive. The
radiosensitivity of cells increases with the reproductive
rate and decreases with the level of differentiation,
therefore the nerve and muscle tissue in the extremities
is the least radiosensitive tissue in the body. The radiosensitivity of the exposed tissue is included in the calculation of effective dose in this report. Due to the low
radiosensitivity of extremities to radiation, it would be
optimal if future clinical studies were to select calcifications located in a limb as one inclusion criteria for
evaluation of therapeutic efficacy using CT [30].
There are a few limitations to this pilot study: first,
relatively few patients with calcifications were available
at our Center for imaging. Another limitation is the lack
of information to provide validation of this method
(intra and inter rater reliability, validity, responsiveness).
However, in a somewhat similar study, assessment of
intrasubject change in lung tissue content over three CT
scans was 2.75% +/−2.29% (mean and SD) [31]. In the
present report, although their CT scans did not document
a significant improvement in the volume of the calcifications in the 7 months between the first and second scan,
the data do suggest that a longer interval between scans
might be more helpful.

Conclusion
We conclude that limited low dose CT provides a safe,
objective measurement of calcifications in JIIM. Each
study was found to deliver less radiation than a single
chest xray due to the low dose technique, limited field of
view, and relative radio-insensitivity of extremities [32].

Fig. 3 Change in the volume of calcifications: Six of the ten patients, who were compliant, did have a decreased calcification volume from
2.32 ± 1.77 cm3 on the first scan to 1.00 ± 0.92 cm3 on the second scan 6 months later scan with an average decrease of 1.32 cm3. The other
four non-compliant patients had variable changes in the volume of their calcifications
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We speculate that this method may be a useful research
tool to monitor progression and regression of calcifications. The four slice CT method offers the possibility of
detecting and documenting change in the volume of
calcifications in children over time, and may be a useful
adjunct in assessing the child’s response to therapy.
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